Home
Resources
Follow portfolio news
...

Vivacy joins forces with Shanghai Pharmaceuticals for a new breakthrough in the Chinese aesthetics market

Published on
13/11/2024
Amended on
23/3/2026
0
minute(s)
Odyssey 2022
Vivacy
Founded in 2007 by French entrepreneur Waldemar Kita, Vivacy has established itself as a world leader in dermal fillers, with injectable products based on hyaluronic acid, a component naturally present in the human body. Vivacy stands out for its patented Class III medical devices, which combine ease of injection and high quality, bringing safety and satisfaction to patients. With a patient retention rate of over 90%, Vivacy also offers specialized training courses for healthcare professionals.
By
Charles Pinsolle
Charles Pinsolle
Vivacy joins forces with Shanghai Pharmaceuticals for a new breakthrough in the Chinese aesthetics market
This article has been automatically translated. Please excuse any inaccuracies or translation errors.
Dieser Artikel wurde automatisch übersetzt. Bitte entschuldigen Sie etwaige Ungenauigkeiten oder Übersetzungsfehler.
Questo articolo è stato tradotto automaticamente. Ci scusiamo per eventuali inesattezze o errori di traduzione.

To strengthen its international development, Vivacy, a company present in the Vintage Altaroc Odyssey 2022, has signed a strategic distribution agreement with Shanghai Pharmaceuticals, China's largest importer of medicines and a leading player in the pharmaceutical field. This strategic partnership with the Chinese market comes at a time when Vivacy is continuing to expand in a sector driven by growing global demand.

An alliance to consolidate Vivacy's presence in Asia

Thanks to this partnership with Shanghai Pharmaceuticals, Vivacy is closer to Chinese professionals and consumers to meet the growing demand for quality medical aesthetic solutions. This collaboration enables Vivacy to extend its expertise and quality standards beyond its traditional markets, as the appeal of aesthetic care continues to grow in Asia.

With a solid reputation built on high-quality products and a patient-oriented approach, Vivacy sees this expansion as an opportunity to play an active part in China's aesthetic revolution. Shanghai Pharmaceuticals, already well established in this market, will facilitate the introduction of Vivacy's hyaluronic acid range, guaranteeing robust local support and optimal access to products.

Other episodes on this topic

Explore our content collections, which bring together different formats around a single subject/issue/theme.
No articles in this category yet.
No items found.
Europe
Rest of the world
Healthcare
Welcome to Altaroc
To provide you with a tailored experience, we invite you to complete your profile.
Your profile
country of tax residence
Select
choosenCountry
Preferred language
Select
choosenLang
Your investor profile
Financial intermediary or Professional investor
Financial advisors, wealth management advisors, private bankers, or any other investment service providers.
Qualified Investor or Altaroc Investor
Experienced Investor or Altaroc Investor
Private investors who have already invested in Altaroc who have a minimum investment capacity of €100,000.
Private investors who have already invested in Altaroc who have a minimum investment capacity of €250,000.
Inexperienced investor
Individual investors with an investment capacity of less than €100,000.
Individual investors with an investment capacity of less than €250,000.
Institutional investor
Pension funds, retirement funds, asset management firms, and single-family offices.
Scroll down to accept General Terms and Conditions
The webpage you are trying to access is not available in your country.